Applied Genetic (AGTC)

NASDAQ
Currency in USD
Disclaimer
0.394
0.000(0.00%)
Closed
Day's Range
0.3700.400
52 wk Range
0.2302.825
Prev. Close
0.394
Open
0.37
Day's Range
0.37-0.4
52 wk Range
0.23-2.825
Volume
0
Average Vol. (3m)
1,276,048
1-Year Change
19.27%
Shares Outstanding
32,057,504
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More

Applied Genetic Company Profile

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in phase 1/2 clinical trials; and achromatopsia that is in phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. Applied Genetic Technologies Corporation was incorporated in 1999 and is based in Alachua, Florida with an additional location in Cambridge, Massachusetts.

Income Statement